Facebook Follow AMS on Linkedin Follow us on Twitter @amsCoolAgain AMS on Instagram

Estradot and Estalis to remain on the PBS

13 September 2021

Back in May, Sandoz, the supplier of Estradot and Estalis applied to delist these medications from the Pharmaceuticals Benefits Scheme (PBS) as they were not financially viable. The AMS in collaboration with the Royal Australian and New Zealand College of Obstetricians and Gynaeocologists (RANZCOG) and the Endocrine Society of Australia (ESA) wrote to Minister Hunt expressing our concern about access to Estradot and Estalis and the potential health outcomes if these medications were to be delisted from the PBS.

Following further discussions, Sandoz agreed to apply to the Pharmaceutical Benefits Advisory Committee (PBAC) for a price increase instead of delisting Estradot and Estalis from the PBS. Again, in collaboration with RANZCOG and ESA, AMS wrote a joint letter of support to PBAC for a price increase, rather than them being delisted from the PBS.

AMS is now happy to advise that the PBAC has agreed to the price increase for Estradot and Estalis from 1 October. This price increase means that these medications will remain on the PBS and support continuous and sustainable supply to the Australian market. While many women will need to pay more for these medications from 1 October, importantly, women on a healthcare card will only need to pay the concession price. A letter from Sandoz is attached for further information.

pdfHCP Letter Estradot Estalis Sep 2021

Print Email

Search

Facebook Follow AMS on Linkedin Follow us on Twitter @amsCoolAgainAMS on Instagram